Evaluation of a multiplexed immunoassay for assessing long-term humoral immunity Orthopoxviruses

IF 4.5 3区医学 Q2 IMMUNOLOGY Vaccine Pub Date : 2024-10-18 DOI:10.1016/j.vaccine.2024.126453

Bethany Hicks , Scott Jones , Helen Callaby , Daniel Bailey , Claire Gordon , Tommy Rampling , Catherine Houlihan , Ezra Linley , Simon Tonge , Clarissa Oeser , Rachael Jones , Marcus Pond , Ravi Mehta , Deborah Wright , Bassam Hallis , Cathy Rowe , Ashley Otter

{"title":"Evaluation of a multiplexed immunoassay for assessing long-term humoral immunity Orthopoxviruses","authors":"Bethany Hicks , Scott Jones , Helen Callaby , Daniel Bailey , Claire Gordon , Tommy Rampling , Catherine Houlihan , Ezra Linley , Simon Tonge , Clarissa Oeser , Rachael Jones , Marcus Pond , Ravi Mehta , Deborah Wright , Bassam Hallis , Cathy Rowe , Ashley Otter","doi":"10.1016/j.vaccine.2024.126453","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The 2022 Monkeypox virus (MPXV) global outbreak boosted development of multiple serological assays to aid understanding of Mpox immunology.</div></div><div><h3>Objectives</h3><div>The study aimed to assess a multiplexed solid-phase electrochemiluminescence immunoassay (Meso Scale Discovery (MSD)) for simultaneous detection of antibodies against MPXV, including A35, E8 and M1 antigens, along with corresponding Vaccina Virus (VACV) homologues and demonstrate its accuracy in assessing antibody titres post-vaccination and infection.</div></div><div><h3>Methods</h3><div>Assay performance was assessed for simultaneous detection of antibodies against MPXV and corresponding VACV antigens. Sensitivity and specificity were evaluated with paediatric negatives (<em>n</em> = 215), pre- and post-IMVANEX vaccinated (<em>n</em> = 80), and MPXV (Clade IIb, <em>n</em> = 39) infected serum samples.</div></div><div><h3>Results</h3><div>The assay demonstrated high specificity (75.68 % (CI: 69.01–81.29) - 95.98 % (CI:92.54–97.87)) and sensitivity (62.11 % (CI:52.06–71.21) - 98.59 % (CI:92.44 %–99.93 %)) depending on the Orthopoxvirus antigen. Preferential binding was observed between MPXV-infected individuals and MPXV antigens, while vaccinated individuals exhibited increased binding to VACV antigens. These results highlight differential binding patterns between antigen homologues in related viruses.</div></div><div><h3>Conclusion</h3><div>Overall, this assay demonstrates high sensitivities in detecting antibodies for multiple relevant MPXV and VACV antigens post-infection and post-vaccination, indicating its utility in understanding immune responses to Orthopoxviruses in current and future outbreaks and evaluating the immunogenicity of new-generation Mpox-specific vaccinations.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"42 26","pages":"Article 126453"},"PeriodicalIF":4.5000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X24011356","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The 2022 Monkeypox virus (MPXV) global outbreak boosted development of multiple serological assays to aid understanding of Mpox immunology.

Objectives

The study aimed to assess a multiplexed solid-phase electrochemiluminescence immunoassay (Meso Scale Discovery (MSD)) for simultaneous detection of antibodies against MPXV, including A35, E8 and M1 antigens, along with corresponding Vaccina Virus (VACV) homologues and demonstrate its accuracy in assessing antibody titres post-vaccination and infection.

Methods

Assay performance was assessed for simultaneous detection of antibodies against MPXV and corresponding VACV antigens. Sensitivity and specificity were evaluated with paediatric negatives (n = 215), pre- and post-IMVANEX vaccinated (n = 80), and MPXV (Clade IIb, n = 39) infected serum samples.

Results

The assay demonstrated high specificity (75.68 % (CI: 69.01–81.29) - 95.98 % (CI:92.54–97.87)) and sensitivity (62.11 % (CI:52.06–71.21) - 98.59 % (CI:92.44 %–99.93 %)) depending on the Orthopoxvirus antigen. Preferential binding was observed between MPXV-infected individuals and MPXV antigens, while vaccinated individuals exhibited increased binding to VACV antigens. These results highlight differential binding patterns between antigen homologues in related viruses.

Conclusion

Overall, this assay demonstrates high sensitivities in detecting antibodies for multiple relevant MPXV and VACV antigens post-infection and post-vaccination, indicating its utility in understanding immune responses to Orthopoxviruses in current and future outbreaks and evaluating the immunogenicity of new-generation Mpox-specific vaccinations.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

评估长期体液免疫正畸病毒的多重免疫测定。

背景：2022年猴痘病毒（MPXV）在全球爆发，促进了多种血清学检测方法的开发，以帮助人们了解猴痘免疫学：该研究旨在评估一种多重固相电化学发光免疫测定（Meso Scale Discovery (MSD)），用于同时检测MPXV抗体，包括A35、E8和M1抗原，以及相应的疫苗病毒（VACV）同源物，并证明其在评估疫苗接种后和感染后抗体滴度方面的准确性：评估同时检测 MPXV 和相应 VACV 抗原抗体的检测性能。用儿科阴性样本（n = 215）、接种 IMVANEX 疫苗前后的样本（n = 80）和感染 MPXV（Clade IIb，n = 39）的血清样本评估灵敏度和特异性：该检测方法的特异性（75.68 % (CI: 69.01-81.29) - 95.98 % (CI:92.54-97.87 %)）和灵敏度（62.11 % (CI:52.06-71.21) - 98.59 % (CI:92.44 %-99.93 %)）都很高，具体取决于正射血病毒抗原。在 MPXV 感染者与 MPXV 抗原之间观察到了优先结合，而疫苗接种者与 VACV 抗原的结合则有所增加。这些结果凸显了相关病毒抗原同源物之间的不同结合模式：总之，该检测方法在感染后和接种疫苗后检测多种相关的 MPXV 和 VACV 抗原抗体方面表现出很高的灵敏度，表明它在了解当前和未来疫情爆发时对正痘病毒的免疫反应以及评估新一代 Mpox 特异性疫苗的免疫原性方面具有实用价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.